Details zur Publikation |
| Kategorie | Textpublikation |
| Referenztyp | Zeitschriften |
| DOI | 10.1016/j.vaccine.2005.01.081 |
| Titel (primär) | Tumour-dentritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results |
| Autor | Trefzer, U.; Herberth, G.
; Wohlan, K.; Milling, A.; Thiemann, M.; Sharav, T.; Sparbier, K.; Sterry, W.; Walden, P. |
| Quelle | Vaccine |
| Erscheinungsjahr | 2005 |
| Department | IMMU |
| Band/Volume | 23 |
| Heft | 17-18 |
| Seite von | 2367 |
| Seite bis | 2373 |
| Sprache | englisch |
| Keywords | Tumour vaccine; Melanoma; T cell; Immune monitoring; Immune escape; Clinical trial |
| Abstract | Hybrid cell vaccines of autologous tumour cells fused with allogenic dendritic cells (DC) combine the tumour's antigenicity with the immune-stimulatory capacity of mature dendritic cells and allogenic MHC class II molecules to activate T cell help and induce tumour-specific cytotoxic T cells. This concept was tested in a clinical trial with melanoma stage III and IV patients. Seventeen patients were evaluated: one experienced complete, one partial response and six stable disease with long survival times. Eleven of fourteen patients, clinical responders and non-responders alike, mounted high-frequency T cell responses to various tumour-associated antigens. Failing clinical responses correlated with loss of antigenicity. |
| dauerhafte UFZ-Verlinkung | https://www.ufz.de/index.php?en=20939&ufzPublicationIdentifier=3846 |
| Trefzer, U., Herberth, G., Wohlan, K., Milling, A., Thiemann, M., Sharav, T., Sparbier, K., Sterry, W., Walden, P. (2005): Tumour-dentritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results Vaccine 23 (17-18), 2367 - 2373 10.1016/j.vaccine.2005.01.081 |
|